Sierra Oncology (NASDAQ:SRRA – Get Rating) was downgraded by investment analysts at HC Wainwright from a “buy” rating to a “neutral” rating in a research report issued on Wednesday, The Fly reports. They currently have a $55.00 price target on the biotechnology company’s stock. HC Wainwright’s price objective would suggest a potential upside of 0.60% […]
Sierra Oncology, Inc. (NASDAQ:SRRA – Get Rating)’s stock price reached a new 52-week high on Wednesday . The stock traded as high as $37.83 and last traded at $37.83, with a volume of 9214 shares trading hands. The stock had previously closed at $36.40. A number of brokerages have commented on SRRA. Oppenheimer boosted their […]
Wall Street brokerages expect that Sierra Oncology, Inc. (NASDAQ:SRRA – Get Rating) will post earnings of ($0.91) per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Sierra Oncology’s earnings. The lowest EPS estimate is ($0.97) and the highest is ($0.85). Sierra Oncology reported earnings per share of […]
Sierra Oncology, Inc. (NASDAQ:SRRA – Get Rating) traded down 3.5% on Friday following insider selling activity. The stock traded as low as $35.49 and last traded at $35.57. 3,688 shares were traded during trading, a decline of 99% from the average session volume of 255,010 shares. The stock had previously closed at $36.85. Specifically, major […]
Sierra Oncology, Inc. (NASDAQ:SRRA – Get Rating) was the target of a significant growth in short interest in February. As of February 28th, there was short interest totalling 1,090,000 shares, a growth of 26.4% from the February 13th total of 862,600 shares. Based on an average daily trading volume, of 1,120,000 shares, the days-to-cover ratio […]